Please be as discriptive as possible. (Break it down dummy style please) (side q
ID: 3165181 • Letter: P
Question
Please be as discriptive as possible. (Break it down dummy style please) (side question: if it’s recombinant would cloning be involved why or why not?)Regarding the posted article “Hepatitis E vaccine debuts: Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases” (Nature 10/29/2012):
The workers made a recombinant subunit vaccine in E. coli host cells. Hepatitis E virus is a non-enveloped virus that contains an RNA genome and icosahedral capsid. Describe a stepwise process that could be used to develop and produce the vaccine. You have purified hepatitis E virus genomic RNA as starting material.
Please be as discriptive as possible. (Break it down dummy style please) (side question: if it’s recombinant would cloning be involved why or why not?)
Regarding the posted article “Hepatitis E vaccine debuts: Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases” (Nature 10/29/2012):
The workers made a recombinant subunit vaccine in E. coli host cells. Hepatitis E virus is a non-enveloped virus that contains an RNA genome and icosahedral capsid. Describe a stepwise process that could be used to develop and produce the vaccine. You have purified hepatitis E virus genomic RNA as starting material.
Please be as discriptive as possible. (Break it down dummy style please) (side question: if it’s recombinant would cloning be involved why or why not?)
Regarding the posted article “Hepatitis E vaccine debuts: Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases” (Nature 10/29/2012):
The workers made a recombinant subunit vaccine in E. coli host cells. Hepatitis E virus is a non-enveloped virus that contains an RNA genome and icosahedral capsid. Describe a stepwise process that could be used to develop and produce the vaccine. You have purified hepatitis E virus genomic RNA as starting material.
Explanation / Answer
Hepatitis E virus (HEV), a non-enveloped, positive-sense, single-stranded RNA virus, is a major cause of enteric hepatitis. Classified into the family Hepeviridae, HEV comprises four genotypes (genotypes 1-4), which belong to a single serotype. We describe a monoclonal antibody (mAb), 8G12, which equally recognizes all four genotypes of HEV, with ?2.53–3.45 nM binding affinity. The mAb 8G12 has a protective, neutralizing capacity, which can significantly block virus infection in host cells. Animal studies with genotypes 1, 3 and 4 confirmed the cross-genotype neutralizing capacity of 8G12 and its effective prevention of hepatitis E disease
Although China is the first country that has licensed HEV vaccine, the reported cases of hepatitis E since 2012 have only declined by 7.58% (29,202 cases in 2011, 26,988 cases in 2014).89 According to data released by China Notifiable Disease Reporting System (CNDRS) in 2014, hepatitis E still consisted about 50% of the reported acute hepatitis cases, and the ratio had been increasing annually, the number of HE cases reported after Hecolin® licensing had remained at similar high level